Targeted Combo Plus Chemo Doubles Survival in BRAF-Mutated CRC

(MedPage Today) — CHICAGO — First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved survival outcomes compared with standard of care in patients with BRAF V600E-mutated metastatic colorectal…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115814

Author :

Publish date : 2025-05-30 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Targeted Combo Plus Chemo Doubles Survival in BRAF-Mutated CRC

Cannabis Use, Even Edibles, May Raise Risk

Terminated! The Risky Clause Hidden in Physician Contracts

Related Posts

Worldwide Burden of Skin Cancer; Patient-Delivered Weight Loss Management

A Doctor’s Bias Creeps Into the Courtroom

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-Line

Worldwide Burden of Skin Cancer; Patient-Delivered Weight Loss Management

A Doctor’s Bias Creeps Into the Courtroom

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-Line

Chemo-Free Doublet in First-Line Boosts PFS in Triple-Negative Breast Cancer

Immunotherapy drug doubles cancer survival in breakthrough trial

Categories

Archives